GeNeuro SA

EPA:GNRO.PA

0.07 (EUR) • At close September 16, 2024
Bedrijfsnaam GeNeuro SA
Symbool GNRO.PA
Munteenheid EUR
Prijs 0.065
Beurswaarde 1,922,523
Dividendpercentage 0%
52-weken bereik 0.056 - 2.35
Industrie Biotechnology
Sector Healthcare
CEO Mr. Jesus Martin-Garcia
Website https://www.geneuro.com

An error occurred while fetching data.

Over GeNeuro SA

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is

Vergelijkbare Aandelen

Acticor Biotech SAS logo

Acticor Biotech SAS

ALACT.PA

0.375 EUR

Valbiotis SA logo

Valbiotis SA

ALVAL.PA

1.322 EUR

Poxel S.A. logo

Poxel S.A.

POXEL.PA

0.525 EUR

Affluent Medical SA logo

Affluent Medical SA

AFME.PA

1.88 EUR

ABIONYX Pharma SA logo

ABIONYX Pharma SA

ABNX.PA

1.244 EUR

Crossject Société Anonyme logo

Crossject Société Anonyme

ALCJ.PA

2.3 EUR

Financiële Gegevens

Cijfers zijn in miljoenen (EUR)

Cijfers zijn in miljoenen (EUR)